Caffeine and headaches

Frary CD, Johnson RK, Wang MQ: Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc 2005, 105:110–113.

Barone JJ, Roberts HR: Caffeine consumption. Food Chem Toxicol 1996, 34:119–129.

Somani SM, Gupta P: Caffeine: a new look at an age-old drug. Int J Clin Pharmacol Ther Toxicol 1988, 26:521–533.

Fredholm BB, Battig K, Holmen J, et al.: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharm Rev 1999, 51:83–133.

Spiller GA: Caffeine. Boca Raton, FL: CRC Press; 1998.

Migliardi JR, Armellino JJ, Friedman M, et al.: Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994, 56:576–586.

Lipton RB, Stewart WF, Ryan RE, et al.: Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain. Arch Neurol 1998, 55:210–217.

Diener HC, Pfaffenrath V, Pageler L, et al.: The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005, 25:776–787.

Thithapandha A: Effect of caffeine on the bioavailability and pharmacokinetics of aspirin. J Med Assoc Thai 1989, 72:562–566.

Iqbal N, Ahmad B, Janbaz KH, et al.: The effect of caffeine on the pharmacokinetics of acetaminophen in man. Biopharm Drug Dispos 1995, 16:481–487.

Laska EM, Sunshine A, Mueller F, et al.: Caffeine as an analgesic adjuvant. JAMA 1984, 251:1711–1718.

Zhang WY: A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Saf 2001, 24:1127–1142.

Ward N, Whitney C, Avery D, Dunner D: The analgesic effects of caffeine in headache. Pain 1991, 44:151–155.

Diamond S, Balm TK, Freitag FG: Ibuprofen plus caffeine in the treatment of tension-type headache. Clin Pharmacol Ther 2000, 68:312–319.

Camann WR, Murray RS, Mushlin PS, Lambert DH: Effects of oral caffeine on postdural puncture headache. A double-blind, placebo-controlled trial. Anesth Analg 1990, 70:181–184.

Yucel A, Ozyalcin S, Talu GK, et al.: Intravenous administration of caffeine sodium benzoate for postdural puncture headache. Reg Anesth Pain Med 1999, 24:51–54.

Esmaoglu A, Akpinar H, Uqur F: Oral multidose caffeineparacetamol combination is not effective for the prophylaxis of postdural puncture headache. J Clin Anesth 2005, 17:58–61.

Dodick DW, Mosek AC, Campbell JK: The hypnic (“alarm clock”) headache syndrome. Cephalalgia 1998, 18:152–156.

Dreisbach RH, Pfeiffer C: Caffeine-withdrawal headache. J Lab Clin Med 1943, 28:1212–1219.

Silverman K, Evans SM, Strain EC, Griffiths RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992, 327:1109–1114.

Juliano LM, Griffiths RR: A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) 2004, 176:1–29.

The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 2004, 24(Supp 1):1–160.

Evans SM, Griffiths RR: Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J Pharmacol Exp Ther 1999, 289:285–294.

Fennelly M, Galletly DC, Purdie GI: Is caffeine withdrawal the mechanism of postoperative headache? Anesth Analg 1991, 72:449–453.

Kendler KS, Prescott CA: Caffeine intake, tolerance, and withdrawal in women: a population-based twin study. Am J Psychiatry 1999, 156:223–228.

Courturier EGM, Hering R, Steiner TJ: Weekend attacks in migraine patients: caused by caffeine withdrawal? Cephalalgia 1992, 12:99–100.

Mosek A, Korczyn AD: Yom Kippur headache. Neurology 1995, 45:1953–1955.

Sjaastad O, Bakketeig LS: Caffeine-withdrawal headache. The Vaga study of headache epidemiology. Cephalalgia 2004, 24:241–249.

Usmani OS, Belvisi MG, Patel HJ, et al.: Theobromine inhibits sensory nerve activation and cough. FASEB J 2005, 19:231–233.

Kallenborn R, Weigel S, Jensen E, Hühnerfuss H: Pharmaceutical residues in the northern Norwegian environment. Geological Society of America Abstracts with Programs 2003, 35:143.

Griffiths RR, Chausmer AL: Caffeine as a model drug of dependence: recent developments in understanding caffeine withdrawal, the caffeine dependence syndrome, and caffeine negative reinforcement. Jpn J Neuropsychopharmacol 2000, 20:223–231.

Hughes JR, Oliveti AH, Liguori A, et al.: Endorsement of DSM-IV dependence criteria among caffeine users. Drug Alcohol Depend 1998, 52:99–107.

Satel S: Is caffeine addictive? A review of the literature. Am J Drug Alcohol Abuse 2006, 32:493–502.

Feinstein AR, Heinemann LAJ, Dalessio D, et al.: Do caffeinecontaining analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000, 68:457–467.

Daly JW, Fredholm BB: Caffeine—an atypical drug of dependence. Drug Alcohol Depend 1998, 51:199–206.

Schuh KJ, Griffiths RR: Caffeine reinforcement: the role of withdrawal. Psychopharmacology (Berl) 1997, 130:320–326.

Rogers PJ, Martin J, Smith C, et al.: Absence of reinforcing, mood and psychomotor performance effects of caffeine in habitual non-consumers of caffeine. Psychopharmacology (Berl) 2003, 167:54–62.

Shirlow MJ, Mathers CD: A study of caffeine consumption and symptoms: indigestion, palpitations, tremor, headache and insomnia. Int J Epidemiol 1985, 14:239–248.

Boardman HF, Thomas E, Millson DS, Croft PR: Psychological, sleep, lifestyle, and comorbid associations with headache. Headache 2005, 45:657–669.

Takeshima T, Ishizaki K, Fukuhara Y, et al.: Populationbased door-to-door survey of migraine in Japan: the Daisen study. Headache 2004, 44:1–12.

Bigal M, Sheftell FD, Rapoport AM, et al.: Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002, 42:575–581.

Scher AI, Stewart WF, Lipton RB: Caffeine as a risk factor for chronic daily headache. Neurology 2004, 63:2022–2027.

Wiendels NJ, Knuistingh NA, Rosendaal FR, et al.: Chronic frequent headache in the general population: prevalence and associated factors. Cephalalgia 2006, 26:1434–1442.

Hering-Hanit R, Gadoth N: Caffeine-induced headache in children and adolescents. Cephalalgia 2003, 23:332–335.

Dunwiddie TV, Masino SA: The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001, 24:31–55.

Mathew RJ, Wilson WH: Caffeine induced changes in cerebral circulation. Stroke 1985, 16:814–817.

Burnstock G: Pathophysiology of migraine: a new hypothesis. Lancet 1981, 1:1397–1399.

Burnstock G: The role of adenosine triphosphate in migraine. Biomed Pharmacother 1989, 43:727–736.

Wolff HG: Headache and Other Pain. Oxford: Oxford University Press; 1948.

Guieu R, Devaux C, Henry H, et al.: Adenosine and migraine. Can J Neurol Sci 1998, 25:55–58.

Brown SG, Waterer GW: Migraine precipitated by adenosine. Med J Aust 1995, 162:389–391.

Hawkes CH: Dipyridamole in migraine. Lancet 1978, 2:153.

Hardebo JE, Edvinsson L: Adenine compounds: cerebrovascular effects in vitro with reference to their possible involvement in migraine. Stroke 1979, 10:58–62.

Conlay LA, Conant JA, deBros F, Wurtman R: Caffeine alters plasma adenosine levels. Nature 1997, 389:136–137.

Couturier EGM, Laman DM, van Duijn MAJ, van Duijn H: Infl uence of caffeine and caffeine withdrawal on headache and cerebral blood velocities. Cephalalgia 1997, 17:188–190.

Jones HE, Herning RI, Cadet JL, Griffiths RR: Caffeine withdrawal increases cerebral blood flow velocity and alters quantitative electroencephalography (EEG) activity. Psychopharmacology (Berl) 2000, 147:371–377.

Field AS, Laurienti PJ, Yen Y-F, et al.: Dietary caffeine consumption and withdrawal: confounding variables in quantitative cerebral perfusion studies. Radiology 2003, 227:129–135.

Fredholm BB: Adenosine actions and adenosine receptors after 1 week treatment with caffeine. Acta Physiol Scand 1982, 115:283–286.

Johansson B, Georgiev V, Lindstrom K, Fredholm BB: A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res 1997, 762:153–164.

Varani K, Portaluppi F, Merighi S, et al.: Caffeine alters A2A adenosine receptors and their function in human platelets. Circulation 1999, 99:2499–2502.

Jacobson KA, von Lubitz DKJE, Daly JW, Fredholm BB: Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 1996, 17:108–113.

Taiwo YO, Levine JD: Further confirmation of the role of adenylyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 1991, 44:131–135.

Santicioli P, Del Bianco E, Maggi CA: Adenosine A1 receptors mediate the presynaptic inhibition of calcitonin gene-related peptide release by adenosine in the rat spinal cord. Eur J Pharmacol 1993, 231:139–142.

Carruthers AM, Sellers LA, Jenkins DW, et al.: Adenosine A1 receptor-mediated inhibition of protein kinase Ainduced calcitonin gene-related peptide release from rat trigeminal neurons. Mol Pharmacol 2001, 59:1533–1541.

Sebastiao AM, Ribeiro JA. Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci 2000, 21:341–346.

Hohoff C, Marziniak M, Lesch KP, et al.: An adenosine A2A receptor gene haplotype is associated with migraine with aura. Cephalalgia 2007, 27:177–181

Ghelardini C, Galeotti N, Bartolini A: Caffeine induces central cholinergic analgesia. Naunyn Schmiedebergs Arch Pharmacol 1997, 356:590–595.

Sawynok J, Reid A: Neurotoxin-induced lesions to central serotonergic, noradrenergic and dopaminergic systems modify caffeine-induced antinociception in the formalin test and locomotor stimulation in rats. J Pharmacol Exp Ther 1996, 277:646–653.

Garrett BE, Griffiths RR: The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav 1997, 57:533–541.